Growth momentum Samsung Biologics has robust 2026 revenue and operating profit growth across multiple quarterly reports, indicating expanding capacity and customer demand. This suggests opportunities to engage with new biologics programs seeking scalable CDMO support and faster time-to-market.

Global expansion The opening of a Netherlands sales office in 2026 signals a push into Western Europe and closer regional coverage. This creates a foothold for European biotech firms seeking local CDMO partnerships and faster regulatory alignment.

Sustainability edge Consistent recognition in Dow Jones Best-in-Class Indices highlights a sustainability and responsible practices advantage. Use this to target sustainability-minded sponsors and biopharma companies prioritizing ESG-aligned suppliers.

Capacity leadership Samsung Biologics markets itself as having the largest capacity and fastest throughput among CDMOs. This can be pitched to programs with high-volume manufacturing needs or compressed timelines seeking reliable scale.

Full-service appeal As a fully integrated CDMO offering development to manufacture for biologics, Samsung Biologics can win deals requiring end-to-end support, potentially reducing vendor fragmentation for clients pursuing end-to-end timelines and regulatory readiness.